Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization. READ MORE
Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization.
Patients with rheumatoid arthritis are at increased risk of serious infections, myocardial infarction, and coronary heart disease, an analysis of Medicare claims data suggests.
Despite a trend toward increased metric use, approximately 50% of patients with RA are not routinely assessed with a disease activity metric, according to the results of a recent survey.
As initial therapy for relapsing-remitting multiple sclerosis, rituximab works better than commonly used disease-modifying treatments, hint results of a comparative real-world effectiveness study from Sweden.
Research in Review
A recent comparative effectiveness study examined the relationship of ACPA status and accrued economic burden for patients with rheumatoid arthritis.
Recent research suggests that 40% of older patients with rheumatoid arthritis still take opioids regularly as of 2014.
Researchers developed a method of identifying candidates for dose reduction of disease modifying anti-rheumatic drugs.
A cost-effectiveness analysis showed that patients with RA who switch from an antirheumatic drug to a biologic drug are likely to increase costs of care.
The first guidelines on the use of disease-modifying therapies in multiple sclerosis have been issued by the European Committee for Research and Treatment of Multiple Sclerosis and the European Academy of Neurology.